Post Date:Aug-22-22
miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling
Author: AcceGen R&D TeamDate Published: 22-Aug-22
- Authors: Hu Han, Yan Li, Wan Qin, Lu Wang, Han Yin, Beibei Su, Xianglin Yuan
- Journal: Cancer Cells International
- DOI: 10.1186/s12935-022-02460-x
- Cited AcceGen Product/Service: miR-199b-3p antagomir
Copyright - Unless otherwise stated all contents of this website are AcceGen™ All Rights Reserved – Full details of the use of materials on this site please refer to AcceGen Editorial Policy – Guest Posts are welcome, by submitting a guest post to AcceGen you are agree to the AcceGen Guest Post Agreement – Any concerns please contact marketing@accegen.com
